FNCHQ (Finch Therapeutics Group) Total Assets: $45.58 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Total Assets?

Finch Therapeutics Group FNCHQ 12 Total Assets is $45.58 Mil as of Jun. 2024. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Finch Therapeutics Group's Total Assets for the quarter that ended in Jun. 2024 was $45.58 Mil.

Total Assets is connected with ROA %. Finch Therapeutics Group's annualized ROA % for the quarter that ended in Jun. 2024 was -40.42%. Total Assets is also linked to Revenue through Asset Turnover. Finch Therapeutics Group's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Finch Therapeutics Group  (OTCPK:FNCHQ) Total Assets Explanation

Total Assets is connected with ROA %.

Finch Therapeutics Group's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=-19.336/( (50.092+45.576)/ 2 )
=-19.336/47.834
=-40.42 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Finch Therapeutics Group's Asset Turnover for the quarter that ended in Jun. 2024 is

Asset Turnover
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (50.092+45.576)/ 2 )
=0/47.834
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Finch Therapeutics Group Total Assets Related Terms

Finch Therapeutics Group Total Assets Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Total Assets Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
103.57 165.34 225.37 162.94 55.37

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.86 59.49 55.37 50.09 45.58
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Finch Therapeutics Group's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=22.886+32.487
=55.37

Finch Therapeutics Group's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (Q: Jun. 2024 )+Total Liabilities (Q: Jun. 2024 )
=14.219+31.357
=45.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $45.58 Mil mean?
Finch Therapeutics Group (FNCHQ) has a Total Assets of $45.58 Mil as of Jun. 2024. The total amount of assets as recorded on a company's balance sheet. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Total Assets too high?
Finch Therapeutics Group's current Total Assets is $45.58 Mil. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Total Assets compare to CRIS and LSB?
Finch Therapeutics Group's Total Assets of $45.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Total Assets is $45.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Total Assets of $45.58 Mil. The current Total Assets is $45.58 Mil. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Total Assets is $45.58 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price